Kigali, Rwanda — November 03, 2025 — At the AORTIC 2025 Conference in Hammamet,
Tunisia, Bio Usawa was recognized by the organizers for our shared commitment to
expanding opportunities for African scientists.

As Dr. Miriam Mutebi, outgoing President of the African Organization for Research and
Training in Cancer (AORTIC), aptly noted, “In Africa, talents are everywhere. What we were
missing is opportunities — that’s what we are opening now.”

This vision lies at the heart of the newly launched AORTIC–Bio Usawa Microgrant Program,
which supports early and mid-career African cancer researchers to advance locally led,
evidence-based solutions.

It is a targeted step toward a future where solutions to Africa’s cancer challenges are
imagined, tested, and led right here on the continent.

By investing in homegrown innovation and scientific leadership, Bio Usawa and many likeminded partners are contributing to a stronger, more self-reliant ecosystem for cancer
research and care.

Learn more by connecting with Dr. Menghis Bairu at the following panel session:

Tuesday, 4 November 2025: 15:00-17:00 – PANEL: Digital Technology Platforms,
Affordable Technologies and Innovative Therapies (Hall 4).

About Bio Usawa
Bio Usawa is Africa’s pioneering biotechnology company dedicated to democratizing access to life-saving biotherapeutics. Headquartered in Kigali, Rwanda, the company develops,
licenses, and manufactures affordable monoclonal antibodies and biosimilars targeting
cancer, diabetes complications, infectious diseases, and autoimmune conditions.